Sign in

Nathalie Albert

@nathaliealbert.bsky.social
58 followers 25 following 0 posts

Professor of Nuclear Medicine with a focus on Neurooncology, passionate for PET imaging and theranostics, founder of the Female Excellence in Medicine Network (FEMclub)

PostsRepliesMedia
Reposted by Nathalie Albert
LMU München @lmu.de · 12/05/2025
An international research team led by nuclear medicine specialist @nathaliealbert.bsky.social (@lmu-klinikum.bsky.social) and oncologist Matthias Preusser (@meduniwien.ac.at) have taken an important step towards improving the diagnosis and therapy monitoring of brain metastases. Read more here:
lmu.de
Nuclear medicine: better diagnosis and therapy for brain metastases
An international team of researchers lays down the first ever standardized criteria for the use of amino acid PET for brain metastases.
0144
Reposted by Nathalie Albert
Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 15/05/2025
🥳 Today, the first patient was successfully randomized in the international LUMEN-1 trial, the first prospective randomized study to evaluate the efficacy of [177Lu]Lu-DOTATATE in recurrent meningioma! www.eortc.org/research_fie... @nathaliealbert.bsky.social @eortc.org
051
Reposted by Nathalie Albert
Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 09/02/2025
📡 Listen to the @neuroonc.bsky.social podcast with @nathaliealbert.bsky.social on measurable disease with FET-PET vs. MRI in glioblastoma: soc-neuro-onc.libsyn.com/measurable-d...! @eanoassociation.bsky.social @eortc.bsky.social
053
Reposted by Nathalie Albert
Nuclear Medicine and Neurooncology (NMN) @nmnsymposium.bsky.social · 11/02/2025
💥 @nathaliealbert.bsky.social highlighting the randomized LUMEN-1 trial on Lu-DOTATE in recurrent #meningioma in @naturemedicine.bsky.social: nature.com/articles/d41.... @eortc.bsky.social @eanoassociation.bsky.social @neuroonc.bsky.social @icomeningioma.bsky.social #theranostics
093
Reposted by Nathalie Albert
Jan Werner @jmwerner.bsky.social · 29/11/2024
🚨 Study by Galldiks et al. showing metabolic response to vorasidenib in IDH-mut gliomas using PET monitoring. This highlights FET PET’s potential to provide earlier & more informative assessments of treatment response than MRI in patients receiving IDH-inhibitors academic.oup.com/noa/advance-...
academic.oup.com
Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomas
SUMMARY. The phase-3 INDIGO trial demonstrated that the IDH inhibitor vorasidenib significantly prolonged progression-free survival and delayed interventio
1147
Reposted by Nathalie Albert
femclub.bsky.social @femclub.bsky.social · 07/12/2024
Welcome to FEMclub – where women in medicine come together to inspire, innovate, and make waves! 💥 Join us and become part of the community! buff.ly/3Vhkwi4 #FEMclub #rolemodel #rolemodels #vorbild #femalescientist #equality #medicine #med
042
Reposted by Nathalie Albert
femclub.bsky.social @femclub.bsky.social · 03/12/2024
Welcome to the FEMclub @bsky.app! At FEMclub, we believe in surrounding ourselves with brilliance, inspiration, and diverse perspectives. 🧠💡 We love to inspire and to get inspired by our amazing FEMclub members.  We're certainly all in the right room here.  Join us!  www.femclubmed.org
021
Reposted by Nathalie Albert
EANO @eanoassociation.bsky.social · 24/11/2024
That’s a wrap on #SNO2024 in Houston! ✨ The #EANO team had an amazing time sharing knowledge, meeting outstanding colleagues and friends, and being part of such an inspiring event. Thank you, @neuroonc.bsky.social, for hosting this great conference! #neurooncology #braintumor #cancer #btsm
0349